Claire Mazumdar, the chief executive officer of Bicara Therapeutics Inc (NASDAQ:BCAX), sold 8,234 shares of the company’s common stock over a three-day span from March 4 to March 6, 2026, totaling approximately $154,324 in proceeds. The transactions executed at weighted average prices ranged from $18.7338 to $18.7508 per share.
The share dispositions occurred while BCAX shares were trading close to their 52-week high of $19.71. The stock has returned 10% over the last week and has gained 53% over the past six months, reflecting recent momentum in the shares.
These sales followed the exercise of stock options by Mazumdar, who exercised options to acquire the same 8,234 shares of Bicara Therapeutics common stock at an exercise price of $3.7898 per share, for a combined acquisition cost of $31,205.
After completing the option exercise and the subsequent open-market sales, Mazumdar directly owns 339,392 shares of Bicara Therapeutics Inc.
Valuation and financial context
According to an InvestingPro assessment cited with the company’s figures, Bicara appears overvalued at current market levels when measured against its Fair Value estimate. The firm carries a market capitalization of approximately $1.2 billion but remains unprofitable, reporting negative earnings.
In other material corporate developments, Bicara recently completed a significant public offering that raised roughly $172.5 million. The offering comprised 8,581,250 shares of common stock and pre-funded warrants. The sale was priced at $16.00 per share for common stock and $15.9999 per share for pre-funded warrants.
Prior to the completion of the offering, the company had announced pricing that aimed to generate about $150 million in gross proceeds before accounting for underwriting discounts and commissions. The offering documentation also indicated the company launched the transaction with the potential to extend it by granting underwriters a 30-day option to purchase up to an additional $22.5 million of shares.
Analyst view and clinical update
Citizens has reaffirmed its Market Outperform rating on Bicara Therapeutics and maintained a $31.00 price target. That target was supported by analysis using discounted earnings per share and revenue multiples.
On the clinical front, Bicara presented long-term follow-up data at the 2026 MHNCS conference, a development referenced in the company’s own analysis and investor materials.
Taken together, the insider transactions, the sizable capital raise, the analyst rating and the clinical follow-up data represent the latest pieces of information market participants will weigh as they assess Bicara’s prospects. The company’s market capitalization, unprofitable status, and an InvestingPro Fair Value rating that signals overvaluation are notable context for investors monitoring BCAX.